Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates by Black, P. A. et al.
RESEARCH ARTICLE Open Access
Whole genome sequencing reveals genomic
heterogeneity and antibiotic purification in
Mycobacterium tuberculosis isolates
PA Black1†, M. de Vos1†, GE Louw1, RG van der Merwe1, A. Dippenaar1, EM Streicher1, AM Abdallah2, SL Sampson1,
TC Victor1, T. Dolby3, JA Simpson3, PD van Helden1, RM Warren1*† and A. Pain2†
Abstract
Background: Whole genome sequencing has revolutionised the interrogation of mycobacterial genomes. Recent
studies have reported conflicting findings on the genomic stability of Mycobacterium tuberculosis during the evolution
of drug resistance. In an age where whole genome sequencing is increasingly relied upon for defining the structure of
bacterial genomes, it is important to investigate the reliability of next generation sequencing to identify clonal variants
present in a minor percentage of the population. This study aimed to define a reliable cut-off for identification of low
frequency sequence variants and to subsequently investigate genetic heterogeneity and the evolution of drug resistance
in M. tuberculosis.
Methods: Genomic DNA was isolated from single colonies from 14 rifampicin mono-resistant M. tuberculosis isolates, as
well as the primary cultures and follow up MDR cultures from two of these patients. The whole genomes of the M.
tuberculosis isolates were sequenced using either the Illumina MiSeq or Illumina HiSeq platforms. Sequences were
analysed with an in-house pipeline.
Results: Using next-generation sequencing in combination with Sanger sequencing and statistical analysis we defined a
read frequency cut-off of 30 % to identify low frequency M. tuberculosis variants with high confidence. Using this cut-off
we demonstrated a high rate of genetic diversity between single colonies isolated from one population, showing that by
using the current sequencing technology, single colonies are not a true reflection of the genetic diversity within a whole
population and vice versa. We further showed that numerous heterogeneous variants emerge and then disappear
during the evolution of isoniazid resistance within individual patients. Our findings allowed us to formulate a model for
the selective bottleneck which occurs during the course of infection, acting as a genomic purification event.
Conclusions: Our study demonstrated true levels of genetic diversity within an M. tuberculosis population and showed
that genetic diversity may be re-defined when a selective pressure, such as drug exposure, is imposed on M. tuberculosis
populations during the course of infection. This suggests that the genome of M. tuberculosis is more dynamic than
previously thought, suggesting preparedness to respond to a changing environment.
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Background
Whole genome sequencing (WGS) has revolutionised
the detailed interrogation of mycobacterial genomes at
base-pair resolution. Application of this technology has
provided novel insights into the evolution of members
of the Mycobacterium tuberculosis complex [1–3]. More
recently, WGS has been applied to investigate the evolution
of drug resistance based on the hypothesis that additional
mutational events may precede or occur concurrently with
known resistance conferring mutations [4–8]. A number of
recent studies have assessed the genomic stability of M.
tuberculosis during the evolution of drug resistance
(Reviewed by Trauner et al., 2014) [4], producing diamet-
rically opposed results. Some studies have demonstrated
genomic stability [6, 7, 9, 10], while more recent reports
have shown genomic instability with the emergence of add-
itional genetic variants independent of those observed in
drug target genes conferring resistance [5, 11–14]. Various
studies have demonstrated the acquisition of known resist-
ance conferring mutations in the M. tuberculosis genome
during the course of infection and subsequent drug treat-
ment. This highlights the potential of M. tuberculosis to di-
versify and adapt under selective pressure [11, 13, 15]. In
other work, WGS analysis of serially collected sputum sam-
ples of Tuberculosis (TB) patients provided overwhelming
evidence of the presence of drug resistant sub-populations
[5]. This study emphasised the need to investigate the im-
plications of inter- and intra-host M. tuberculosis genetic
diversity for transmission and disease outcomes [5]. The
presence of drug resistant sub-populations is a major con-
cern when considering the variable sensitivity of standard
genetic and microbiological tests for the diagnosis of drug
resistance M. tuberculosis [16].
It is important to note that the identification of sub-
populations within the context of WGS is dependent on
the read frequency cut-off values used in the standard vari-
ant filtering approach. Typically, these frequency cut-off
values are set at >70 %, implying that only variants fixed
within a population are identified i.e. variants present at
only >70 % of the sequencing reads are analysed [6, 8]. Fail-
ure to adjust these algorithms to accommodate for the
presence of low-frequency sub-populations has led authors
to conclude that the population structure of M. tubercu-
losis is homogeneous [6, 8, 17, 18]. By using an alternative
variant calling approach (a minimum read depth of 50 and
a minimum variant frequency of 4 %) a recent study dem-
onstrated the rapid expansion and collapse of different
sub-populations that evolved in parallel during the evolu-
tion of extensively drug resistant (XDR-TB) [14]. However,
while WGS is increasingly being used to investigate drug
resistance and evolution in M. tuberculosis, there is still
uncertainty surrounding the error rate of sequencing, read
alignment and the detection of variants. In an age where
WGS is increasingly relied on for defining the structure of
bacterial genomes, it is important to investigate the reliabil-
ity of next-generation sequencing reads where a variant is
only present in a minor percentage of the sequencing
reads. This therefore questions the threshold at which
underlying populations, as indicated by the percentage of
sequencing reads supporting a variant allele, can be con-
firmed as true variants as opposed to sequencing errors.
This study aimed to define a reliable cut-off for iden-
tification of heterogeneous variants from WGS data.
Subsequently this cut-off was used to investigate: 1)
heterogeneity in single colonies isolated from 13 rifam-
picin mono-resistant M. tuberculosis clinical isolates,
and 2) the evolution of isoniazid resistance in rifampi-
cin mono-resistant isolates in 2 patients.
Results
Strains were initially selected on the basis of clinical
diagnostic records, then subjected to further analysis to
confirm their resistance profiles and strain genotypes.
Phenotypic drug resistance testing of the parental isolates
(n = 13) and their associated single colonies (n = 36)
confirmed the rifampicin mono-resistant profile in all
cases. As expected, all isolates carried a mutation in the
rpoB gene; genotyping of parental isolates identified one
of the following mutations in the rpoB gene: Ser531Leu,
His526Tyr or Leu533Pro (Table 1). These mutations
were retained in the corresponding single colonies after
selection on agar plates containing rifampicin. IS6110
genotyping and spoligotyping revealed that the rifampi-
cin mono-resistant isolates originated from different
genetic backgrounds (LCC, Haarlem, Beijing and EAI),
representing the broad strain diversity circulating in
the Western Cape, South Africa. Genotyping by IS6110
Table 1 Genotypic characterisation of M. tuberculosis clinical
isolates used for the investigation into genomic heterogeneity
Isolate name rpoBa Spoligotype classification
R160 Ser531Leu LCC
R376 Ser531Leu Haarlem
R458 Ser531Leu Unknown/unique
R486 Leu533Pro Beijing
R631 His526Tyr Unknown/unique
R637 Ser531Leu Beijing
R641 Leu533Pro Beijing
R721 Ser531Leu Beijing
R912 His526Tyr EAI
R965 Leu533Pro Beijing
R966 His526Tyr Beijing
R1035 Ser531Leu LAM
R1415 His526Tyr Beijing
LCC low copy clade, EAI East African Indian, LAM Latin American Mediterranean
aAmino acid change according to the Escherichia coli rpoB gene sequence
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Table 2 Validation of variants with a read frequency ranging between 20 and 100 % using targeted PCR and sanger sequencing
Genea Sanger chromatogram result Read frequency (%) Sanger result
Rv2316 Single peak 127/127 (100.0) True
Rv1703c Single peak 152/154 (98.7) True
Rv0820 Single peak 193/200 (96.5) True
Rv3220c Single peak 129/134 (96.3) True
Rv0537c Single peak 98/126 (77.8) True
Rv2692 Single peak 102/142 (71.8) True
Rv1521 Double peaks 157/222 (70.7) True
Rv0521 Double peaks 117/159 (68.8) True
Rv1904 Double peaks 119/181 (65.7) True
Rv1230c Double peaks 96/155 (61.9) True
Rv3086 Double peaks 84/145 (57.9) True
Rv3083 Double peaks 55/95 (57.9) True
Rv1429 Double peaks 74/129 (57.4) True
Rv2577 Double peaks 33/61 (54.1) True
Intergenic (1093238) Double peaks 89/168 (53.0) True
Rv3391 Double peaks 57/113 (50.4) True
Rv2689c Double peaks 59/123 (48.0) True
Rv0970 Double peaks 48/104 (46.2) True
Rv2173 Double peaks 54/130 (41.5) True
Rv1929c Double peaks 52/128 (40.6) True
Rv2459 Double peaks 18/45 (40.0) True
Rv2984 Double peaks 34/89 (38.2) True
Rv1894c Double peaks 36/95 (37.9) True
Rv1316c Double peaks 72/198 (36.4) True
Rv1021 Double peaks 42/119 (35.3) True
Rv2544 Double peaks 50/151 (33.1) True
Rv3772 Double peaks 47/147 (32.7) True
Rv3861 Double peaks 38/119 (31.9) True
Rv3780 Double peaks 30/106 (31.9) True
Rv0491 Double peaks 44/138 (31.9) True
Rv2957 Single peak 47/154 (30.5) False
Rv1549 Double peaks 42/138 (30.4) True
Rv3703c Single peak 37/126 (29.4) False
Rv0594 Double peaks 61/202 (29.2) True
Rv0372c Single peak 85/296 (28.7) False
Rv1479 Single peak 34/120 (28.3) False
Rv0780 Single peak 44/159 (27.7) False
Rv0092 Double peaks 47/170 (27.6) True
Rv0688 Double peaks 56/209 (26.8) True
Rv0282 Single peak 54/205 (26.3) False
Rv0663 Double peaks 41/158 (25.9) True
Rv0522 Double peaks 66/263 (25.1) True
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also showed that the parental isolates and single col-
onies were identical, confirming the absence of mixed
infection.
Identifying a reliable cut-off to detect genomic
heterogeneity
To define a reliable cut-off for heterogeneous variant de-
tection, we employed a combination of WGS and statis-
tical analyses of parental isolates and their associated
single colonies. Single colonies were obtained by plating
serial dilutions of the parental isolate onto 7H10 agar
containing 2 μg/ml RIF. Two to three single colonies
isolated from each of the 13 parental rifampicin mono-
resistant M. tuberculosis isolates (Table 1) were selected
and subjected to WGS analysis. This analysis of 36 single
colonies revealed the presence of a total of 153 possible
sequence variants between corresponding single colonies
using M. tuberculosis H37Rv as the alignment standard.
To determine whether a variant which was present in less
than 100 % of the reads reflected the presence of either
genetically distinct subpopulations or sequencing artefacts,
46 of the 153 possible variants were selected for validation
by Sanger sequencing (Table 2). All 6 variants present in
≥71.8 % of the reads were verified with a single chromato-
gram peak demonstrating that only the dominant nucleo-
tide was detected. In addition, 25 variants present in
between 30.5 and 70.7 % of the reads were also deter-
mined to contain two nucleotides indicated by the pres-
ence of two chromatogram peaks. Of the 16 variants with
a read frequency between 20.3 and 30.5 %, 7 were shown
to be false positives as only a single chromatogram peak
was observed. We investigated the frequency of the 7 false
positive variants across all of the single colonies as recur-
rence of these variants in other genomes might suggest
that the false variants were called due to mapping errors.
Only one of the 7 variants (in Rv0282) was found to be re-
current and identified in 22 of the single colonies.
We performed a receiver operator characteristic (ROC)
curve analysis to define a reliable cut-off for the identifica-
tion of true heterogeneous variants. ROC curve analysis
disproved the null hypothesis, with an area under the
curve (AUC) of 0.835 (95 % CI: 0.722 – 0.948). A cut-off
value of 30 % read frequency was defined with a true posi-
tive value of 0.795 and a false positive value of 0.143 i.e. a
true positive rate of 79.5 % and a false positive rate of
14.3 % (Fig. 1). Using the conventional cut-off value of
70 % there would be a true positive rate of 17.9 % and a
false positive rate of 0 %. Accordingly, we defined a cut off
for the description of true heterogeneity at a defined nu-
cleotide position as ≥30 % i.e. if a variant identified in at
least 30 % of the Illumina sequencing reads (after filtering
and GenomeView analysis), it is likely that the variant is
truly present within the genome of a sub-population of
bacilli. Using this analysis we also defined a variant with a
read frequency of greater than 70 % to be fixed within a
population.
Identifying genomic heterogeneity in individual colonies
from rifampicin mono-resistant isolates
We next applied the ≥30 % variant frequency cut-off value
to assess genomic heterogeneity within and between indi-
vidual colonies. Using this cut-off value this analysis 36 of
single colonies revealed the presence of a total of 114
possible sequence variants between corresponding single
colonies using M. tuberculosis H37Rv as the alignment
standard. From the 114 possible variants, 42 were found to
have a read frequency of greater than 70 %, while 72 were
Fig. 1 Validation of variants identified by Illumina sequencing. Analysis
of Sanger sequencing alignments and corresponding chromatograms
was used to validate the presence of homo- and heterogeneous variants
identified by Illumina sequencing. Variants present in either the
sequencing file or in the chromatogram (Additional file 2: Table S2)
were scored as true variants while sequences which remained wild-type
were scored as false
Table 2 Validation of variants with a read frequency ranging between 20 and 100 % using targeted PCR and sanger sequencing
(Continued)
Rv1660 Double peaks 52/239 (21.8) True
Rv1627c Single peak 34/161 (21.1) False
Rv0654 Double peaks 34/167 (20.4) True
Rv2934 Double peaks 47/232 (20.3) True
aAll variant positions and WGS results are listed in the supplementary data (Additional file 2: Table S2)
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found to have a read frequency of between 30 and 70 %
(Table 3, (Additional file 1)). The number of variants iden-
tified was independent of the strain background, and
ranged from 0 to 19 in different clinical isolates. Import-
antly, genomic heterogeneity was observed both within sin-
gle colonies (where a variant is only present in a proportion
of the reads) and between single colonies isolated from one
parent.
Comparing single colonies and the entire population
isolated from sputum
WGS data was available for four of the parental M. tuber-
culosis isolates used to make the single colonies. There-
fore, to determine whether the single colonies reflected
the genetic heterogeneity of the parent isolate, we com-
pared the WGS of the single colonies from four rifampicin
mono-resistant M. tuberculosis clinical isolates to the
sequences of their corresponding parent population
(R721, R912, R965 and R486). As shown in Fig. 2 this
comparison identified 6, 4, 4 and 2 variants that were
unique to the single colonies relative to the parental ge-
nomes for R721, R965, R486 and R912, respectively. These
variants were shared between all of the single colonies cul-
tured from their corresponding parental isolates. In
addition, the individual single colonies also harboured
unique variants that were absent in the corresponding par-
ental isolates as well as absent in the other related single
colonies. Conversely, the parental isolates also each har-
boured unique variants that were absent in all correspond-
ing single colonies (Fig. 2). Together these results suggest
that all of the genomic variants identified as unique to the
single colonies were masked by the dominant population
present in the parent isolates.
Intra-patient evolution of drug resistance
Having established the utility of our analytical approach in
identifying inter- and intra-isolate variation, we next went
on to analyse genome heterogeneity during the evolution
of drug resistance. Here, we analysed MDR isolates (R807
and R1210) collected approximately 7 and 11 months after
the rifampicin mono-resistant isolates R721 and R912,
respectively (Table 4). We investigated the heterogeneity of
SNPs across the genome of the rifampicin mono-resistant
and MDR entire populations relative to the M. tuberculosis
H37Rv reference genome. We subsequently compared this
list of SNPs between the rifampicin mono-resistant and
MDR isolates to identify variants unique to each isolate as
well as the evolutionary events associated with the emer-
gence of drug (isoniazid) resistance (Table 5).
For patient 1 numerous heterogeneous variants were
identified in the rifampicin mono-resistant isolate, R721,
while there were no heterogeneous variants observed in
the follow-up MDR isolate, R807 (Fig. 3a, Table 4). Since
the primary difference between these two isolates is the
presence of a katG mutation (Table 5), these results
suggest that the heterogeneous variants present in
R721 were ‘lost’ during the acquisition of isoniazid re-
sistance. Patient 2 shows contrasting results: the rifam-
picin mono-resistant isolate, R912, was shown to have
no heterogeneous variants while its follow-up MDR
isolate, R1210, harboured 5 (Fig. 3b). The variants
shown to be unique to R912 were all present at a
Table 3 Variants identified in corresponding single colonies derived from different clinical isolates
Single colony 1 Single colony 2 Single colony 3
Totala Fixedb Heteroc Totala Fixedb Heteroc Totala Fixedb Heteroc Total variation
R160 5 2 3 4 3 1 - - - 9
R376 3 1 2 8 2 6 6 1 5 17
R458 3 3 0 5 2 3 3 0 3 11
R486 0 0 0 2 0 2 - - - 2
R631 5 0 5 6 0 6 8 0 8 19
R637 0 0 0 0 0 0 0 0 0 0
R641 9 9 0 3 0 3 6 0 6 18
R721 0 0 0 4 0 4 0 0 0 4
R912 4 4 0 6 3 3 7 7 0 17
R965 4 4 0 1 1 0 - - - 5
R966 5 0 5 1 0 1 6 0 6 12
R1035 0 0 0 0 0 0 0 0 0 0
R1415 0 0 0 0 0 0 0 0 0 0
aTotal number variants unique between the corresponding single colonies
bFixed variants as defined as having a read frequency of ≥ 70 %
cHeterogeneous variants as defined as having a read frequency < 70 % and ≥ 30 %
-A third single colony was not available for the comparison
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variant frequency of greater than 70 %. Interestingly,
two variants shown to be fixed within the rifampicin
mono-resistant population, with a variant frequency of
100 %, were found to be present at a lower frequency
within the MDR population (Fig. 3b). This finding indi-
cates that two fixed variants in R912 may have been lost
in R1210. These results revealed the acquisition and loss
of numerous heterogeneous variants (Table 5), suggesting
continuous genome evolution despite the evolutionary
bottle neck imposed by the isoniazid selective pressure.
Finally, we compared the WGS data of MDR isolates
to the single colonies generated from the rifampicin
mono-resistant parental isolates. This comparison failed
to identify any of the single colony specific genomic var-
iants in the MDR isolate.
Discussion
Our study aimed to use WGS in combination with Sanger
sequencing and statistical analyses to define a reliable cut-
off for heterogeneous variant detection. Our data enabled
Fig. 2 Genetic diversity between parental populations and their corresponding single colonies. a The R721 parental population had 8 unique variants
relative to all three colonies. While all three colonies shared 6 variants which were unique to the colonies relative to the parental population, each colony
also harboured unique variants relative to the other colonies. Similarly, for (b) the R912 parental population had 8 unique variants relative to all
three colonies. While all three colonies only shared 2 variants, each colony also harboured unique variants relative to the other colonies. (c) For
R965, the parental population had 1 unique variant relative to both colonies, while the colonies shared 4 variants which were unique relative to
the parental population. Similarly, the two colonies for R486 (d) shared 4 variants which were unique relative to the parental population. The R486
parental population had 1 unique variant relative to the other colonies
Table 4 M. tuberculosis clinical isolates demonstrating a number of unique variants between rifampicin mono-resistant and MDR
isolates during in vivo evolution of isoniazid resistance
Patient Isolate
name
Phenotypic
resistance
Collection
date
rpoBc katG inhA
promoter
Spoligotype
classification
Fixed
variantsa
Heterogeneous
variantsb
Total
variation
1 R721 Rifampicin mono 22/10/2003 Ser531Leu - - Beijing 1 8 9
R807 MDR 19/05/2004 Ser531Leu Gly309Val - Beijing 2 0 2
2 R912 Rifampicin mono 15/09/2004 His526Tyr - - East Africa Indian
(EAI)
7 0 7
R1210 MDR 12/08/2005 His526Tyr - −15 EAI 1 5 6
aFixed variants as defined as having an read coverage of ≥70 %
bHeterogeneous variants as defined as having an read coverage <70 % and ≥30 %
cAmino acid change according to the Escherichia coli rpoB gene sequence
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us to define a read frequency cut off of 30 % for reliable
Illumina sequencing variant frequency filtering i.e. a variant
present in 30 % or more of the sequencing reads can be
considered to be a true variant and not a sequencing error.
At a variant frequency of 30 % there is a true positive of
79.5 % and a false positive rate of 14.3 %. We acknowledge
that there is still a chance that true variants at a frequency
lower than 30 % may be missed due to the limited reso-
lution of Sanger sequencing. For the purpose of our ana-
lyses we regard it of greater importance to exclude false
positives from our analyses than to omit a small amount of
true positives. However, we do not exclude the probability
that this cut-off value may change with increased sequence
read depth. Higher depth of coverage would however not
limit the detection of false positive variants as the 7 false
positive variants identified in this study were not associated
with lower mean genome coverage. Furthermore, by defin-
ing a cut-off it allowed us to use a relaxed variant filtering
approach to investigate the presence of sub-populations in
M. tuberculosis clinical isolates.
Table 5 Isolate specific variants identified in rifampicin mono-resistant and MDR M. tuberculosis isolates of patient 1 and 2
Isolate Locus Gene Amino acid
change
Coverage of
variant (%)
Gene description Functional categoryC
Patient 1 R721a Rv0435c I397L 50 Putative conserved ATPase Cell wall and cell
processes
Rv0435c D395Y 50 Putative conserved ATPase
Rv0668 rpoC V1039A 30 DNA-directed RNA polymerase RpoC
(RNA polymerase beta’ subunit).
Information pathways
Rv1850 ureC Q11K 48 Urease alpha subunit UreC (urea amidohydrolase) Intermediary metabolism
and respiration
Rv1850 ureC Q11R 49 Urease alpha subunit UreC (urea amidohydrolase)
Rv3218 Y174H 66 Conserved protein Conserved hypotheticals
Rv2004c Ins AAG 43 Conserved protein Conserved hypotheticals
Rv3563 fadE32 Ins AC 40 Probable acyl-CoA dehydrogenase FadE32 Lipid metabolism
Rv3696c glpK Ins AC 73 Probable glycerol kinase GlpK (ATP:glycerol
3-phosphotransferase)
Intermediary metabolism
and respiration
R807b Rv1908c katG G309V 100 Catalase-peroxidase-peroxynitritase T KatG Virulence, detoxification,
adaptation
Rv3696c glpK T91I 80 Probable glycerol kinase GlpK (glycerokinase) (GK) Intermediary metabolism
and respiration
Patient 2 R912a Rv1128c G430S 98 Conserved hypothetical protein Insertion sequences and
phages
Rv2236c cobD L269S 97 Probable cobalamin biosynthesis transmembrane
protein CobD
Intermediary metabolism
and respiration
Rv2664 H22Q 99 Hypothetical protein Conserved hypotheticals
Rv2772c E149* 97 Probable conserved transmembrane protein Cell wall and cell
processes
Rv2984 ppk1 P631A 96 Polyphosphate kinase PPK (polyphosphoric acid
kinase)
Intermediary metabolism
and respiration
Rv3391 acrA1 syn (248) 99 Possible multi-functional enzyme with
acyl-CoA-reductase activity AcrA1
Lipid metabolism
Rv3537 kstD syn (378) 98 Probable dehydrogenase Intermediary metabolism
and respiration
R1210b inhA
promoter
−15 45
Rv1484 inhA S94A 70 NADH-dependent enoyl-[acyl-carrier-protein]
reductase InhA (NADH-dependent enoyl-ACP
reductase)
Lipid metabolism
Rv1629 polA syn (146) 45 Probable DNA polymerase I PolA Information pathways
Rv2935 ppsE C582R 69 Phenolpthiocerol synthesis type-I polyketide synthase
PpsE
Lipid metabolism
aRifampicin mono-resistant
bMDR
cFunctional category as classified by Tuberculist (http://genolist.pasteur.fr/TubercuList/ and http://tuberculist.epfl.ch/)
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Using our cut-off of 30 % variant frequency we inves-
tigated the genomic heterogeneity within and between
individual single colonies isolated from rifampicin
mono-resistant M. tuberculosis clinical isolates. To our
knowledge this is the first study that has investigated M.
tuberculosis genomic diversity within single colonies
from a clinical sample at a single time point. We observed
a high rate of genetic diversity between single colonies iso-
lated from the same parental isolate. We acknowledge that
the analysis of only two to three single colonies for each
patient isolate would have limited the anlaysis of the true
heterogeneity in the total population. We also acknowledge
that the selection of these single colonies on media con-
taining rifampicin would have resulted in the loss of vari-
ants representing rifampicin susceptible colonies. This high
rate of genetic diversity seen in our study is in concordance
with previous studies that used relaxed filtering with
regards to variant frequency [5, 12, 14]. Sun et al.
showed that there can be as many as 41 (ranging be-
tween 6 and 41) variants between serial sputum sam-
ples, with 82.7 % of all the variants at frequencies lower
than 20 % (based on statistical evaluation as opposed to
validation by Sanger sequencing) [5]. A study by Bryant
et al. showed seemingly contrasting results using the same
filtering approach to investigate relapse and reinfection
cases [10]. Using a minimum read depth of 4 and read fre-
quency higher than 5 %, little genetic diversity was ob-
served in the relapse cases. However any heterogeneous
positions identified were discarded as mapping errors and
no validation by Sanger sequencing was done. This may
have led to an underestimation of the number of variants,
a possibility highlighted by our findings that heteroge-
neous variants occurring between 30 and 70 % frequency
are likely to be truly present within a population.
Our findings which showed the extent of diversity be-
tween parental isolates and their respective single col-
onies are in agreement with a recent study where in
vitro generated mutants were compared to their drug
susceptible progenitor [19]. Numerous variants only
present in a proportion of the Illumina reads were iden-
tified to be unique to the parental genome. Similar to
our findings the authors showed that in some daughter
cells the mutant allele was lost while in others it was
retained [19]. This suggests that single colonies may not
be a true reflection of the genomic diversity of a clinical
M. tuberculosis isolate. In contrast, WGS of an entire
population may underestimate the extent of genetic di-
versity present in a clinical isolate given the complexity
of the M. tuberculosis population structure. However,
improved read depths may allow for identification of
underlying populations which were undetectable in this
study. The high degree of genetic diversity seen in this
study is similar to that reported elsewhere [5, 12, 14]
and is unlikely to have arisen as a consequence of la-
boratory adaptations. The number of culturing steps
was kept to a minimum and previous WGS data from in
vitro generated mutants in our laboratory showed very
little genetic diversity (data not shown). This is sup-
ported by WGS of six M. tuberculosis H37Rv strains
from multiple laboratories that showed little change
after years of repeated sub-culturing, suggesting gen-
omic stability during in vitro culture [20].
Our results show that single colonies may not be a true
reflection of the genetic diversity present within a clinical
isolate and vice versa. This finding may have important
implications for genomic epidemiology since a recent
study by Didelot et al. (2014) demonstrated the use of
WGS to infer person to person transmission. Underlying
Fig. 3 Heterogeneous positions identified across the whole population genomes relative to M. tuberculosis H37Rv reference genome. aThe rifampicin
mono-resistant isolate (R721) for patient 1 shows numerous heterogeneous variants relative to M. tuberculosis H37Rv while the follow-up MDR isolate
(R807) has none. (b) For patient 2 the rifampicin mono-resist isolate (R912) showed no heterogeneous variants relative to M. tuberculosis H37Rv, while
the follow-up MDR isolate (R1210) had numerous heterogeneous variants. R912 shared 2 variants (Rv0667 and Rv0672) with R1210, where the variant
was present at 100 % in R912 but was a heterogeneous variant in R1210
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populations masked by dominant variants may not truly
be represented in the above method and may therefore be
overlooked when interpreting person to person transmis-
sion [21]. Therefore, this study highlights the importance
of the methods of storage used for M. tuberculosis isolates.
The diversity seen i) within a clinical isolate and ii)
between single colonies isolated from a single M. tubercu-
losis clinical isolate needs to be taken into consideration.
Storage of samples should therefore be carefully consid-
ered based on the research questions which may be asked
in future studies. Numerous studies have stated that single
colonies were isolated from LJ slants for storage and fur-
ther use [9, 22–25], while other studies use clinical isolates
as a whole representative population [5, 8, 10, 11, 13, 14].
These different approaches may impact results obtained
and conclusions drawn.
Having shown genetic diversity between parental pop-
ulations and their single colonies, as well as diversity be-
tween single colonies isolated from the same progenitor,
we next investigated the evolution of isoniazid resist-
ance in M. tuberculosis clinical isolates within two pa-
tients. Initial investigation into genetic heterogeneity in
both rifampicin mono-resistant and MDR isolates relative
to M. tuberculosis H37Rv revealed that there were numer-
ous heterogeneous variants present within the genome.
For patient 1, the rifampicin mono-resistant isolate har-
boured numerous heterogeneous variants, all of which
were unique to this isolate when compared to its paired
MDR isolate. During the acquisition of the katG isoniazid
resistance causing mutation all of these heterogeneous
variants were lost from the population. This finding sug-
gested that the isoniazid selective pressure imposed an
evolutionary bottleneck, resulting in a purification effect
and the loss of heterogeneous variants. Contrasting results
were observed for patient 2, as the 7 apparently fixed
SNPs were lost during the acquisition of the inhA pro-
moter isoniazid resistance causing mutation. Once again,
this finding suggests that isoniazid selective pressure im-
posed an evolutionary bottleneck. The paired MDR iso-
late, R1210, showed a total of 8 heterogeneous variants to
be unique to this isolate when compared to R912, two of
which were fixed within the population of R912. This sug-
gests that these two variants were reverting to wild type,
while other variants were emerging within the popula-
tion. These findings highlight the continuous genome
evolution occurring after an evolutionary bottleneck is
imposed on a population. The M. tuberculosis isolates
from each patient represent two different strain line-
ages, namely Beijing and EAI, suggesting that genetic
diversity observed during the evolution of isoniazid re-
sistance is not limited to one lineage. The MDR isolates
were collected approximately 7 and 11 months after the
initial rifampicin mono-resistant samples were collected
from patients’ 1 and 2, respectively. Unfortunately,
clinical information such as treatment regimens and
treatment adherence was not available to us at the time
of the study, limiting our ability to draw conclusions re-
garding mutation rates and selective pressure.
The loss of an rpoC polymorphism from the rifampicin
mono-resistant isolate from patient 1 (R721) further high-
lights the importance of selective pressure on defining the
genetic population of M. tuberculosis. A proportion of
30 % of the R721 population (based on read frequency)
contained an rpoC mutation while there was no rpoC mu-
tation present in the follow-up MDR isolate (R807). While
variants in the rpoC gene have been speculated to be puta-
tive compensatory mutations [26], this mutation may not
be important for survival since the selective purification
for isoniazid resistance causing mutations resulted in the
loss of this putative compensatory mutation. No additional
compensatory mutations were identified in the WGS data
for the isolates used in this study.
Complementary to our findings are the results observed
in a recent study by Eldholm et al. where it was shown that
the amount of variation between serial isolates from a sin-
gle patient may be higher than that observed between two
patients in a transmission chain [14]. In addition they ob-
served numerous SNPs within the mycobacterial popula-
tion which occurred concurrently with drug resistance
causing mutations, which were termed ‘hitchhiking SNPs’.
Excluding these ‘hitchhiking SNPs’ from their analyses, the
amount of variation between sequential samples decreased,
suggesting that the selective pressure of drug exposure re-
sulted in a purifying effect. Based on these observations the
authors concluded that the presence of populations with
high genetic diversity (variation) facilitated the emergence
of drug resistance, and that selective pressure may be a
driving force in longitudinal genetic diversity [14]. Simi-
larly, a recent study by Bergval et al. hypothesised that a
selection event may result in the fixation of either a wild-
type or mutant allele which was originally present in only a
sub-population of M. tuberculosis isolates [19].
Based on our findings and others’ work, we propose a
model to explain the effect of a selection bottleneck and
random mutations on the population structure of M. tu-
berculosis clinical isolates (Fig. 4). We hypothesise that
during the course of infection numerous genetic mutations
arise within a mycobacterial population and in response to
a selective pressure such as antibiotic exposure, clones
with pre-existing drug resistant mutations are selected.
Cells within the population harbouring drug resistant caus-
ing mutations survive while drug sensitive cells die. During
this process numerous genetic mutations are lost from the
population while mutations which occur concurrently with
drug resistance causing mutations (or ‘hitchhiking SNPs’)
remain [14]. The presence of a selective pressure therefore
creates a selection bottleneck, altering the level of genetic
diversity within the mycobacterial population. Subsequent
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Fig. 4 Proposed model for the effect of a selection bottleneck and random mutations on the population structure of M. tuberculosis clinical isolates. a A
rifampicin mono-resistant clinical M. tuberculosis isolate where each cell comprising the population contains an rpoB mutation. Numerous other genetic
mutations are present thereby creating a diverse population structure. (b) Following the onset of treatment the genetic mutations in the population may
change, and a spontaneous isoniazid resistance causing (for example katG gene or inhA promoter) mutation is selected for and becomes dominant within
the population. (c) Selective pressure of treatment results in the emergence of an isoniazid resistant M. tuberculosis population where each cell contains a
katG mutation. Numerous other genetic mutations are lost during the selection bottleneck resulting in a loss of genetic diversity. (d) Subsequent
replication cycles and population growth results in new genetic mutations arising within the population allowing for new diversification e.g. R1210. Each
cell in this MDR population retains the rpoB and katG resistance causing mutations. Key: x denotes an isoniazid resistance causing mutation (katG)
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growth and the emergence of new SNPs allow for an
increase in genetic diversity once again (Fig. 4). This subse-
quent increase in genetic diversity post selective pressure
is substantiated by our findings that a rifampicin mono-
resistant isolate and its paired MDR isolate each have
numerous unique genetic differences i.e. polymorphisms
are lost from the original rifampicin mono-resistant popu-
lation, while different polymorphisms emerge in the MDR
isolate.
Conclusions
This study investigated two key aspects involved in the
use of next-generation WGS. Firstly, we investigated the
confidence in the validity of variants called during bio-
informatics analysis. Secondly, we investigated the differ-
ence in outputs when utilising a relaxed variant filtering
approach compared to the standard filtering approach.
To our knowledge this is the first study that has investi-
gated M. tuberculosis genomic diversity using single col-
onies isolated from clinical isolates. The surprisingly high
rate of genetic diversity seen in our study is in concord-
ance with previous studies that used a relaxed variant fil-
tering approaches [5, 12, 14]. During the evolution of drug
resistance we observed the emergence and disappearance
of numerous variants within a population. Our findings
allowed us to formulate a model for the selective
bottleneck which occurs during the course of infection,
acting as a genomic purification event. Subsequent
post-bottleneck mycobacterial growth allows for new
genetic diversification to occur. This proposed increase
in diversity suggests that the genome is preparing to re-
spond to a changing environment.
Methods
Strain selection and culture
This study was approved by the Health Research Ethics
Committee of Stellenbosch University with the waiver of
consent to retrospectively collect routine clinical isolates of
M. tuberculosis and limited demographic and diagnostic
data. To ensure patient confidentiality all patient identifiers
were removed. Primary rifampicin mono-resistant clinical
M. tuberculosis isolates were available from 13 patients that
were selected from an extensive longitudinal collection of
drug resistant M. tuberculosis isolates collected in the
Western Cape, South Africa. Two of these patients had fol-
low up isolates which were shown to be multi-drug resist-
ant (MDR) by routine drug susceptibility testing (DST).
Each of the 15 isolates were subjected to isoniazid and
rifampicin DST [27], and Sanger sequencing of the inhA
promoter and katG and rpoB genes (Additional file 2) to
confirm the resistance phenotype. In addition, each isolate
was further genotyped by spoligotyping and IS6110 DNA
fingerprinting using internationally standardized tech-
niques [28, 29].
BACTEC™ Mycobacterial Growth Indicator tubes
(MGIT™ 960) supplemented with Oleic acid-Albumin-
Dextrose-Catalase (OADC) were inoculated with each
isolate and incubated in the BACTEC™ MGIT™ 960 instru-
ment at 37 °C. Following an indication of growth positivity
i.e. when a growth unit of 400 was reached, each MGIT
was incubated at 37 °C for an additional 5 days to allow for
optimal mycobacterial growth. A volume of 500 μl of posi-
tive culture was then used to inoculate a starter culture of
10 ml of 7H9 Middlebrook medium (Becton, Dickinson
Microbiology system, Sparks, USA), supplemented with
10 % albumin-dextrose-catalase (ADC), 0.2 % (v/v) glycerol
(Merck Laboratories, Saarchem, Gauteng, SA) and 0.1 %
Tween80 (Becton, Microbiology systems, Sparks, USA).
Subsequently, the starter cultures were grown in filtered
screw cap tissue culture flasks (Greiner Bio-one, Maybach
Street, Germany) without shaking at 37 °C until an optical
density (OD600) of 0.6–0.8 was reached. Contamination
was assessed by Ziehl-Neelsen (ZN) staining and the
plating of cultures onto blood agar plates. A 100 μl
aliquot of each starter culture for the rifampicin mono-
resistant (n = 13) and paired MDR M. tuberculosis isolates
(n = 2) was plated on 7H10 solid media supplemented
with OADC for DNA extraction. Serial dilutions were pre-
pared and plated on 7H10 solid media supplemented with
OADC and 2 μg/ml rifampicin for selection of single
colonies.
Selection of single colonies
Single colonies were randomly selected from solid media
(7H10 Middlebrook media supplemented with OADC)
containing 2 μg/ml into Middlebrook 7H9 media supple-
mented with ADC and 0.1 % Tween80, and statically
cultured to an OD600 of above 0.8. Each single colony
culture was then sub-cultured on solid media (7H10
Middlebrook media supplemented with OADC) for
DNA extraction. Unnecessary sub-culturing steps were
avoided to minimize the appearance of in vitro adaptive
mutations.
DNA extraction and whole genome sequencing
Genomic DNA was isolated from single colonies for each
rifampicin mono-resistant M. tuberculosis isolate according
to standard protocols [30]. In addition, DNA was isolated
from the primary cultures of the paired M. tuberculosis iso-
lates demonstrating intra-patient evolution of isoniazid
resistance i.e. the parental rifampicin mono-resistant isolate
and a follow-up MDR isolate. Sequencing libraries for all
isolates were constructed using the standard genomic
DNA sample preparation kits from Illumina (Illumina, Inc,
San Diego, CA), according to manufacturer’s instructions.
The whole genomes of the M. tuberculosis isolates were se-
quenced using either the Illumina MiSeq or Illumina
HiSeq platforms.
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Mapping and variant detection
An in-house automated pipeline for M. tuberculosis next
generation sequencing (NGS) analysis was adapted to
allow analysis of the sequencing data (Van der Merwe et
al., manuscript in preparation). The steps involved in the
pipeline are described below.
Quality assessment of the sequencing data (in FASTQ
format) was done using FASTQC [31], followed by trim-
ming of adapters and low-quality bases with a Phred qual-
ity score of less than 20 and filtering for a minimum read
length of 36 using Trimmomatic [32]. A minimum read
length of 36 base pairs was used for subsequent mapping.
Reads were then mapped to the M. tuberculosis H37Rv
genome (Genbank: AL123456) using three different map-
pers namely the Burrows-Wheeler Alignment Tool (BWA)
[33], Novoalign [34] and SMALT [35]. For all libraries se-
quenced, over 98 % of the reference genome was covered
by at least one read and an average depth of coverage of
137× was achieved. The alignment files were subjected to
local realignment and de-duplication using the Genome
Analysis Toolkit (GATK) [36] and Picard [37]. Variants
(Single nucleotide polymorphisms (SNPs) and Insertion/
Deletions (In/Dels)) in coding as well as non-coding re-
gions were then called from each alignment file using
GATK [36], and the overlap of variants identified from all
three alignment files was used for further analysis. Vari-
ants were annotated using annotation data from Tubercu-
list [38]. Variants in repetitive regions, such as pe/ppe and
pe_pgrs gene families, were removed from subsequent
analysis.
In this study we made use of a relaxed variant filtering
approach to allow identification of variants occurring at
varying read frequencies i.e. variants present at varying
proportions within the population. Variants detected by
GATK were filtered for a minimum read depth of 50. An
initial read frequency was not defined to allow for the val-
idation of varying frequencies with Sanger sequencing.
Identified variants were compared between the appro-
priate single colonies selected from the same clinical
isolate. Variants present at a frequency ranging from
20–100 % were selected for validation with Sanger se-
quencing. Variants selected had a minimum read depth
of 50 and a mapping quality score of above 50. All vari-
ants identified in this study were manually inspected
using GenomeView [39].
Confirmation of variants with Sanger sequencing
A subset of 46 randomly selected genomic variants with
read frequencies ranging from 20 to 100 % were validated
by targeted PCR and Sanger sequencing. Oligonucleotide
primers (Additional file 2) were designed using Primer3
[40] to amplify 300–600 base pairs regions flanking the
variant of interest. Briefly, an aliquot of genomic DNA was
added to the following reaction mix containing: 1×Q
buffer, 1× PCR buffer, 2 mM MgCl2, 0.4 mM dNTPs,
50 μM of each primer (Additional file 2) and 1.25U Hot
Star Taq polymerase (Qiagen, San Diego, CA, USA). Amp-
lification was done under the following thermocycling con-
ditions: 15 min (min) denaturation at 95 °C followed by 40
amplification cycles (each cycle: 94 °C for 1 min, 62 °C for
1 min, 1 min extension at 72 °C) and an elongation step of
10 min at 72 °C. PCR products were purified and se-
quenced with the ABI PRISM DNA Sequencer model 377,
Perkin Elmer. Sequence polymorphisms were identified by
comparing the consensus sequence of each isolate to the
corresponding gene sequence of the M. tuberculosis
H37Rv genome using BioEdit (v7.1.3) [41].
Sequencing results were first inspected for the pres-
ence of true variants using the ClustalW multiple align-
ment tool in the BioEdit software. Furthermore, the
chromatograms of each sequencing file were inspected
for the presence of both a wild-type and mutant peak to
identify heterogeneous variants present at a low per-
centage within the population. Chromatograms were
visually inspected for the presence of mixed peaks at the
variant position identified by WGS.
To define a cut-off for the reliability of WGS results
for heterogeneous variants a receiver operating charac-
teristic (ROC) analysis was performed using IBM SPSS
Statistics version 22 (IBM Corp 2013) [42].
Availability of supporting data
The data sets supporting the results of this article are
available in the European Nucleotide Archive with the fol-
lowing accession number: PRJEB9976 and are available at:
http://www.ebi.ac.uk/ena/data/view/PRJEB9976.
The data sets supporting the results for this article are
included within the article (and its additional files).
Additional file 2(.xls) (Primers used for PCR amplifica-
tion and Sanger sequencing) is a table listing all primers
used in the study to validate variants. Additional file 1
(.xls) (Unique variants identified in the single colony
comparison analysis) contains tables of variants identi-
fied in the comparison analysis of the genomes of the
single colonies isolated from clinical specimens.
Additional files
Additional file 1: Unique variants identified in the single colony
comparison analysis. (XLSX 45 kb)
Additional file 2: Primers used for PCR amplification and Sanger
sequencing. (XLSX 15 kb)
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